Synergism of interleukin-12 and interleukin-3 on development of hematopoietic progenitors

Eur J Haematol. 1995 Mar;54(3):172-5. doi: 10.1111/j.1600-0609.1995.tb00210.x.

Abstract

The recently cloned cytotoxic lymphocyte maturation factor [CLMF] also called NK cell stimulatory factor [NKSF] or interleukin-12 [IL-12] has been described as a growth factor for mature lymphoid cells. The present study investigated whether purified recombinant human IL-12 could stimulate CFU colony growth. Source of progenitor cells were peripheral blood cells depleted of adherent, CD2- and CD56-positive cells. RhIL-12 was investigated either alone or in combination with rhIL-3, rhIL-6 and rhGM-CSF. RhIL-12 alone did not support colony formation of myeloid or erythroid progenitors. RhIL-12 in combination with rhIL-3 increased the numbers of BFU-E and CFU-GM. No synergism or additive effect was seen with the combination of rhIL-12 and rhGM-CSF or rhIL-12 and rhIL-6. An additive increase in the number of granulocytic colonies was observed when rhIL-3, rhIL-6 and rhGM-CSF were used together with rhIL-12. Our results therefore suggest that, in addition to being a potent lymphopoietic stimulator, IL-12 acts synergistically with IL-3 in enhancing the sensitivity of hemopoietic progenitors to IL-3.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Erythroid Precursor Cells / drug effects
  • Erythroid Precursor Cells / physiology
  • Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology
  • Hematopoiesis / drug effects
  • Hematopoiesis / physiology
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / physiology*
  • Humans
  • Interleukin-12 / pharmacology*
  • Interleukin-3 / pharmacology*
  • Interleukin-6 / pharmacology

Substances

  • Interleukin-3
  • Interleukin-6
  • Interleukin-12
  • Granulocyte-Macrophage Colony-Stimulating Factor